Implanon NXT® (etonogestrel): Implants have been found rarely in the vasculature and lung. An update on possible risks and complications regarding insertion, localisation, removal and migration

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif

Date: 14 November 2016



There have been post-marketing reports of etonogestrel implants (non-radiopaque and radiopaque) found in the vasculature (including the pulmonary artery) and the chest wall. The package insert for Implanon NXT® has been updated to highlight possible risks and complications regarding insertion, localisation, removal and migration. Instructions for the correct insertion of the implant have been clarified in order to further minimise the risks. A Direct Healthcare Professional Communication (DHPC) has been approved by NPRA for distribution to relevant healthcare professionals to highlight these updates. Please contact the product registration holder, Merck Sharp & Dohme (Malaysia) Sdn. Bhd. for further information including support in training healthcare professionals on the use of Implanon NXT®.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Jumaat 15 Oktober 2021, 15:58:04.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Choose Your Language

Menu Utama